- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02524041
Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism
Based on the evidence that periostin is specifically involved in intra-cortical remodeling control, our working hypothesis is that assessment of its concentration in the serum would be helpful in identifying patients with severe cortical porosity, a critical parameter in bone fragility. Periostin expression by osteoblasts and osteocytes is part of the bone cortical response to anabolic stimuli such as mechanical strain or intermittent increase in parathyroid hormone. However, it remains unknown whether this expression may participate as well to mechanisms that will lead to exaggerated intra-cortical remodeling and subsequent bone loss.
In rare clinical situations in which trans-iliac bone biopsies will be necessary to better understand their bone status in addition to densitometry and biological bone markers assessment, specific analyses using immune-staining techniques will be performed on the bone sample. Data from routine follow-up every six months will be also collected in this specific sub-group.
High resolution peripheral quantitative computerized tomography (HR-pQCT) gives the opportunity of performing a virtual bone biopsy providing information on trabecular and cortical microarchitecture in vivo. These microarchitectural parameters allow a more accurate evaluation of the alteration of the bone structure and therefore of the fracture risk as compared to current tools used in clinical practice such as densitometry. However, the availability of such HRpQCT facilities is limited and there is on-going development on the best way of measuring porosity for example. The definition of a biological profile including key proteins such as periostin and sclerostin involved in porosity mechanisms is therefore of great interest. A better understanding of the relationship between bone matrix components and parathyroid hormone effects also appears as critical. Follow-up of routine evaluation parameters reflecting bone status in a subgroup of specific patients could also provide new and additional information.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Saint-etienne, France, 42000
- Chu de Saint-Etienne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hyperparathyroidism defined by a parathyroid hormone serum level above 65 ng/ml, secondary to Chronic Kidney Disease (CKD) ou vitamin D deficiency
Exclusion Criteria:
- Concurrent bone disease (such as Paget's disease, osteomalacia),
- Other endocrinopathy having an impact on bone metabolism (such as Cushing, hyperthyroidism, severe hypogonadism (except menopause)),
- Current or previous bisphosphonate treatment.
- Transplantation
- parathyroidectomy
- Life expectancy less than 3 months.
- Lack of study understanding.
- Lack of agreement.
- Under legal control.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: secondary hyperparathyroidism
Blood specimen and HR-pQCT for measure bone quality and quantity
|
blood specimen
The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between periostin level and cortical porosity
Time Frame: day 1
|
Correlation between periostin serum level (ng/ml) and cortical porosity.
Cortical porosity (%) is measured by HR-pQCT
|
day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between periostin level and other trabecular and cortical microarchitectural parameters (composite outcome)
Time Frame: day 1
|
Correlation between periostin serum level (ng/ml) and other trabecular and cortical microarchitectural parameters. Cortical microarchitectural parameters are a composite measure measured by HR-pQCT. The measures are : Total volumetric mineral density (mg/ccm HA), Trabecular volumetric mineral density (mg/ccm HA), Cortical volumetric mineral density (mg/ccm HA), Number of bone trabeculae (1/mm), Trabecular thickness (mm), Cortical thickness (mm), Trabecular spacing (mm) o Trabecular distribution (mm) |
day 1
|
Correlation between parathyroid hormon level and other trabecular and cortical microarchitectural parameters (composite outcome)
Time Frame: day 1
|
Correlation between parathyroid hormon serum level (pg/ml) and other trabecular and cortical microarchitectural parameters. Cortical microarchitectural parameters are a composite measure measured by HR-pQCT. The measures are : Total volumetric mineral density (mg/ccm HA), Trabecular volumetric mineral density (mg/ccm HA), Cortical volumetric mineral density (mg/ccm HA), Number of bone trabeculae (1/mm), Trabecular thickness (mm), Cortical thickness (mm), Trabecular spacing (mm) o Trabecular distribution (mm) |
day 1
|
Correlation between Sclerostin serum level and cortical porosity
Time Frame: Day 1
|
Correlation between Sclerostin serum level (ng/ml) and cortical porosity.Cortical porosity (%) is measured by HR-pQCT.
|
Day 1
|
Correlation between parathyroid hormon level and cortical porosity
Time Frame: Day 1
|
Correlation between parathyroid hormon serum level (pg/ml) and cortical porosity.Cortical porosity (%) is measured by HR-pQCT.
|
Day 1
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Thierry THOMAS, MD PhD, Chu de Saint-Etienne
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1308046
- 130560B-22 (Other Identifier: ANSM)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperparathyroidism
-
Nantes University HospitalCompleted
-
Postgraduate Institute of Medical Education and...UnknownPrimary Hyperparathyroidism (PHPT)India
-
Rambam Health Care CampusWithdrawnMultigland Disease in Primary HyperparathyroidismIsrael
-
Nantes University HospitalInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
-
Brigham and Women's HospitalCompletedPrimary HyperparathyroidismUnited States
-
University Hospital Inselspital, BerneCompletedPrimary HyperparathyroidismSwitzerland
-
EFSTATHIOS CHRONOPOULOSCompletedPrimary Hyperparathyroidism
-
M.D. Anderson Cancer CenterUnknownPrimary HyperparathyroidismUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownPrimary Hyperparathyroidism
-
CHU de ReimsUnknownPrimary HyperparathyroidismFrance
Clinical Trials on blood specimen
-
Royal Marsden NHS Foundation TrustImperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal...Recruiting
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; National Institutes of Health (NIH)Not yet recruiting
-
University of California, San FranciscoRecruitingMetastatic Breast Cancer | Lobular Breast CarcinomaUnited States
-
Icahn School of Medicine at Mount SinaiThe Leukemia and Lymphoma SocietyCompletedPolycythemia Vera | Essential ThrombocythemiaUnited States
-
Spectrum Health HospitalsVan Andel Research InstituteCompletedExtracorporeal Membrane OxygenationUnited States
-
University of VirginiaHemoSonics LLCCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)UnknownWilms' Tumor | AniridiaUnited States
-
Mayo ClinicActive, not recruitingCongenital Diaphragmatic Hernia | Myelomeningocele | Spina Bifida | Lower Urinary Tract Obstructive SyndromeUnited States
-
Centre Hospitalier Universitaire de Saint EtienneCompleted